Combination treatment scored EU approval earlier this year
News
Multiple sclerosis trial focusing on people who can’t walk begins recruitment
Trial will evaluate whether Mavenclad can slow the rate of upper limb disability progression
NICE recommends Lilly’s migraine med Emgality
CGRP antagonist approved to prevent migraine in adults with episodic and chronic migraine
AZ’s COVID-19 vaccine produces ‘encouraging’ immune response in older adults
New findings from phase 2 study published in The Lancet
BREAKING NEWS: new data suggests Pfizer/BioNTech’s COVID-19 vaccine is 95% effective
Companies to submit vaccine for emergency authorisation in the US ‘within days’
AZ’s Brilinta reduced rate of stroke and death in high-risk subgroup
New analysis of prespecified subgroup comes from phase III THALES trial
University of Oxford links up with Evox Therapeutics
Collaboration will focus on developing exosome therapeutics for rare diseases
ViiV’s cabotegravir scores breakthrough designation for HIV prevention
Designation is based on results from phase IIb/III HPTN 083 trial
EU signs COVID-19 vaccine deal with CureVac
Initial purchase includes 225 million doses of mRNA-based vaccine
New inquiry launched to assess impact of pandemic on pharmacy services
MPs launch inquiry with view of securing extra support for sector
Lead Pharma and Roche enter €260m collaboration agreement
Companies will develop oral small molecule treatments
Gilead and Novo Nordisk’s NASH trial meets primary endpoint
Drug combinations tested were found to be well tolerated
UK strikes deal for five million doses of Moderna’s COVID-19 vaccine
Initial interim data suggests vaccine is 94.5% effective
NHS launches 40 ‘long COVID’ clinics
It is hoped that the move will help to tackle the persistent symptoms – such as fatigue and brain fog – suffered by people who have developed the condition
£12.2m boost for coronavirus genomic surveillance
The funds will help expand the scale of SARS-CoV-2 virus sequencing in the hope of revealing new opportunities for intervention
